Tag: M.W:300-400

Lin, Chia-Ching; Shen, Yi-Ru; Chang, Chi-Chih; Guo, Xiang-Yi; Young, Yun-Yun; Lai, Ting-Yu; Yu, I-Shing; Lee, Chih-Yuan; Chuang, Tsung-Hsien; Tsai, Hsin-Yue; Hsu, Li-Chung published the artcile< Terminal uridyltransferase 7 regulates TLR4-triggered inflammation by controlling Regnase-1 mRNA uridylation and degradation>, Product Details of C9H13N2O9P, the main research area is terminal uridyltransferase 7 TLR4 regenase1 uridylation inflammation.

Different levels of regulatory mechanisms, including posttranscriptional regulation, are needed to elaborately regulate inflammatory responses to prevent harmful effects. Terminal uridyltransferase 7 (TUT7) controls RNA stability by adding uridines to its 3 ends, but its function in innate immune response remains obscure. Here we reveal that TLR4 activation induces TUT7, which in turn selectively regulates the production of a subset of cytokines, including Interleukin 6 (IL-6). TUT7 regulates IL-6 expression by controlling RNase Regnase-1 mRNA (encoded by Zc3h12a gene) stability. Mechanistically, TLR4 activation causes TUT7 to bind directly to the stem-loop structure on Zc3h12a 3-UTR, thereby promotes Zc3h12a uridylation and degradation Zc3h12a from LPS-treated TUT7-sufficient macrophages possesses increased oligo-uridylated ends with shorter poly(A) tails, whereas oligo-uridylated Zc3h12a is significantly reduced in Tut7-/- cells after TLR4 activation. Together, our findings reveal the functional role of TUT7 in sculpting TLR4-driven responses by modulating mRNA stability of a selected set of inflammatory mediators.

Nature Communications published new progress about Animal gene Role: BSU (Biological Study, Unclassified), PRP (Properties), BIOL (Biological Study) (Tut4). 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Product Details of C9H13N2O9P.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Qiao, Du; Cheng, Luo; Xiaomei, Tian; Baolei, Shi; Yingyi, Li; Hui, Zhang; Shaohua, Bian; Wei, Liu; U, Dai Y; Fangqiong, Deng; Jie, Liu; Shuangning, Liu published the artcile< Effect of ultra-mini percutaneous nephrolithotomy and ShuoTong ureteroscopy on the stress response, inflammatory indices, and urokinase level in patients with polycystic kidney disease complicated with renal calculus.>, Recommanded Product: ((2R,3S,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate, the main research area is .

This study aimed to explore the effects of ultra-mini percutaneous nephrolithotomy (UMP) combined with ShuoTong ureteroscopy on the stress response, inflammation indicators and urokinase levels in patients with polycystic kidney disease and kidney stones. In this study, 42 patients with polycystic kidney disease and kidney stones diagnosed and treated in our hospital from February 2018 to February 2021 were selected as the research objects. They were randomly divided into the control group and the study group, with 21 cases in each group, and the control group adopted Ultra-mini percutaneous nephrolithotomy treatment; the study group was combined with ShuoTong ureteroscopy on the basis of the control group, and compared and analyzed the stress response, inflammation indexes, urokinase level, renal function, complications and stone clearance rate of the two groups of patients. After treatment, the average operation time, channel establishment time, hemoglobin decline, number of puncture channels, and hospital stay in the study group were significantly shorter than those in the control group (P<0.05); after treatment, the reduction in CRP and PCT in the study group was significantly higher than that in the control group The increase of Ang I and Ang II in the control group was significantly lower than that in the control group (P<0.05); the improvement of PGE2, NO, and LPO levels in the study group was significantly higher than that in the control group after treatment (P<0.05); the study group TH, Cys- The levels of C and β2-MG were significantly lower than those of the control group; the UK levels of the study group were significantly lower than those of the control group (P<0.05); the complication rate of 14.29% in the study group after treatment was significantly lower than that of the control group 33.33%; the study group The stone clearance rate of 95.24% was significantly higher than that of the control group 80.95% (P<0.05). In general, UMP combined with ShuoTong ureteroscopy is used to treat polycystic kidney with kidney stones, accurately determine the tip position of the needle sheath, ensure that the needle sheath enters the collection system to adjust its position, reduce patient stress and inflammation, improve safety and feasibility, and is worthy of clinical practice Promote applications. Cellular and molecular biology (Noisy-le-Grand, France) published new progress about 58-97-9. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Recommanded Product: ((2R,3S,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

El-Khayat, Hesham; Kamal, Enas M.; Yakoot, Mostafa; Gawad, Manal A.; Kamal, Naglaa; El Shabrawi, Mortada; Sameh, Yehia; Haseeb, Alaa; Fouad, Yasser; Attia, Dina published the artcile< Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients>, HPLC of Formula: 58-97-9, the main research area is chronic hepatitis effectiveness genotype human.

The sustained virol. response (SVR) rate for the 12-wk sofosbuvir (SOF)/ledipasvir (LVD) treatment of adolescent genotype-4 patients is high. The aim of this study is to evaluate 8 vs. 12-wk treatment efficacy and safety in adolescent genotype-4 patients. In total, 157 chronic hepatitis C-infected adolescent patients (mean age 14±2 years, 62% males) were included in this study. All patients received a morning dose of SOF (400 mg)/LVD (90 mg) as a single tablet for 8 and 12 wk. Laboratory and biochem. monitoring were performed at weeks 4 and 8, end of treatment (8/12) and 12 wk after the end of treatment (SVR12). In total, SVR12 was 98% [95% confidence interval (CI): 96-100] for all treated patients. For patients treated for 12 wk, SVR12 was 97.6% (95% CI: 96-101) (82/84 patients), and 98.6% (95% CI: 93-101) (72/73) patients for those treated for 8 wk. For both regimens, no serious adverse effects, treatment discontinuation or cases of death were detected. The main adverse effects for the 8-wk patient group were fatigue (2.8%), headache (1.4%), nausea (1.4%) and epigastric tenderness (1.4%). For the 12-wk-treated group, adverse events were epigastric tenderness (1.2%), nausea (1.2%), diarrhoea (2.4%) and rash (2.4%). Three patients were lost to follow-up: two were in the 12-wk treatment group and one was in the 8-wk group. All of them reached end of treatment but were lost before SVR12. No relapsers were observed in either group. Eight weeks of treatment of SOF/LVD combination is equally effective and safe as 12 wk in adolescent genotype-4 patients.

European Journal of Gastroenterology & Hepatology published new progress about Chronic hepatitis. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, HPLC of Formula: 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Shiha, Gamal; Esmat, Gamal; Hassany, Mohamed; Soliman, Reham; Elbasiony, Mohamed; Fouad, Rabab; Elsharkawy, Aisha; Hammad, Radi; Abdel-Razek, Wael; Zakareya, Talaat; Kersey, Kathryn; Massetto, Benedetta; Osinusi, Anu; Lu, Sophia; Brainard, Diana M.; McHutchison, John G.; Waked, Imam; Doss, Wah published the artcile< Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt>, HPLC of Formula: 58-97-9, the main research area is hepatitis c virus infection ledipasvir sofosbuvir ribavirin safety Egypt; chronic hepatitis; cirrhosis; genotype.

We evaluated the efficacy and safety of ledipasvir/sofosbuvir alone and with ribavirin for 8 and 12 wk in Egyptian patients with and without cirrhosis, who were infected with hepatitis C virus (HCV) genotype 4, including those who had failed previous treatment with sofosbuvir regimens. Design In this open-label, multicentre, phase III study, treatment-naive patients were randomised to receive 8 or 12 wk of ledipasvir/sofosbuvir±ribavirin. Among treatment-naive patients, SVR12 rates were 95% and 90% for those receiving 8 wk of ledipasvir/sofosbuvir alone and with ribavirin, resp., and 98% for those receiving 12 wk of ledipasvir/sofosbuvir both alone and with ribavirin. Among interferon-experienced patients, SVR rates were 94% for those receiving 12 wk of ledipasvir/ sofosbuvir and 100% for those receiving 12 wk of ledipasvir/sofosbuvir plus ribavirin. All patients previously treated with sofosbuvir regimens who received ledipasvir/sofosbuvir plus ribavirin achieved SVR12. The most common adverse events, headache and fatigue, were more common among patients receiving ribavirin. A mong non-cirrhotic treatment-naive patients with HCV genotype 4, 8 wk of ledipasvir/ sofosbuvir±ribavirin was highly effective. Twelve weeks of ledipasvir/sofosbuvir±ribavirin was highly effective regardless of presence of cirrhosis or prior treatment experience, including previous treatment with sofosbuvir or ledipasvir/sofosbuvir.

Gut published new progress about Anemia. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, HPLC of Formula: 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Chappell, Catherine A.; Scarsi, Kimberly K.; Kirby, Brian J.; Suri, Vithika; Gaggar, Anuj; Bogen, Debra L.; Macio, Ingrid S.; Meyn, Leslie A.; Bunge, Katherine E.; Krans, Elizabeth E.; Hillier, Sharon L. published the artcile< Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study>, SDS of cas: 58-97-9, the main research area is .

Background Hepatitis C virus (HCV) infection is increasing among pregnant women because of the opioid epidemic, yet there are no interventions to reduce perinatal HCV transmission or to treat HCV during pregnancy. Physiol. changes in pregnancy alter the pharmacokinetics of some medications; thus, our aim was to compare the pharmacokinetic parameters of ledipasvir 90 mg plus sofosbuvir 400 mg during pregnancy with non-pregnant women. Methods This was an open-label, phase 1 study of pregnant women with genotype 1 HCV infection and their infants. A reference group of women who had participated in pharmacokinetic studies of ledipasvir-sofosbuvir during phase 2 and 3 trials was used. Participants were enrolled at Magee-Womens Hospital (Pittsburgh, PA, USA) between 23 and 24 wk’ gestation and had a 12-wk course of oral ledipasvir-sofosbuvir (daily 90 mg ledipasvir plus 400 mg sofosbuvir). Three 12-h intensive pharmacokinetic visits were done at 25-26, 29-30, and 33-34 wk’ gestation and individual pharmacokinetics were summarised by geometric mean across the three visits. The primary outcome, analyzed in all participants without suspected dosing errors, was the ledipasvir-sofosbuvir area under the concentration-time curve of the dosing interval (AUCtau) during pregnancy compared with the reference group by geometric mean ratio. This study is registered with ClinicalTrials.gov, NCT02683005. Findings From Oct 1, 2016, to Sept 30, 2018, 29 pregnant women were screened and nine (31%) were enrolled. Eight (89%) women were included in the primary anal. Ledipasvir and sofosbuvir exposures were similar in the pregnant women vs. the non-pregnant reference group (geometric mean ratio of AUCtau ledipasvir 89·3% [90% CI 68·7-116·1]; sofosbuvir 91·1% [78·0-106·3]). Interpretation Ledipasvir-sofosbuvir was safe and effective without clin. meaningful differences in drug exposure among pregnant vs. non-pregnant women.

Lancet Microbe published new progress about 58-97-9. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, SDS of cas: 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Lawitz, Eric; Landis, Charles S; Flamm, Steven L; Bonacini, Maurizio; Ortiz-Lasanta, Grisell; Huang, Jonathan; Zhang, Jie; Kirby, Brian J; De-Oertel, Shampa; Hyland, Robert H; Osinusi, Anu O; Brainard, Diana M; Robson, Richard; Maliakkal, Benedict J; Gordon, Stuart C; Gane, Edward J published the artcile< Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.>, Computed Properties of 58-97-9, the main research area is .

BACKGROUND: There is a medical need for highly effective, safe, and well tolerated treatments for patients infected with hepatitis C virus (HCV) with severe renal impairment. We investigated the safety and efficacy of sofosbuvir with ribavirin or ledipasvir combined with sofosbuvir in a prospective study of patients with genotype 1 or 3 HCV infection and stage 4-5 chronic kidney disease (creatinine clearance by Cockcroft-Gault ≤30 mL/min) who were not on dialysis. METHODS: This phase 2b, open-label, non-randomised, multicentre study in the USA and New Zealand investigated three sequentially enrolled cohorts of patients. Patients were recruited from ten hospitals and clinical research centres and were included if they had genotype 1 or 3 HCV infection, a creatinine clearance less than or equal to 30 mL/min, and were not on dialysis. In cohorts 1 and 2, patients received sofosbuvir (200 mg in cohort 1 and 400 mg in cohort 2) plus ribavirin 200 mg once per day for 24 weeks. In cohort 3, 18 patients received ledipasvir combined with sofosbuvir (90 mg ledipasvir and 400 mg sofosbuvir) once per day for 12 weeks. The primary efficacy endpoint was the proportion of patients achieving sustained virological response 12 weeks after the end of treatment (SVR12). Safety and pharmacokinetic data were also collected. The trial is registered with ClinicalTrials.gov, number NCT01958281, and is completed. FINDINGS: This study was done between Oct 7, 2013, and Oct 29, 2017. In the sofosbuvir plus ribavirin cohorts, 32 patients were screened, of whom 20 were enrolled and assessed for efficacy and safety (ten patients in each cohort). In the ledipasvir plus sofosbuvir cohort, 33 patients were screened, of whom 18 were enrolled and assessed for treatment efficacy and safety. Four (40%, 95% CI 12-74) of ten patients in cohort 1 and six (60%, 26-88) of ten patients in cohort 2 achieved SVR12. All 18 (100%, 82-100) patients in cohort 3 achieved SVR12. Adverse events were mostly mild or moderate in severity. The most commonly reported adverse events overall were headache (eight [21%] of 38 patients), anaemia (seven [18%] of 38 patients), and fatigue (six [16%] of 38 patients). Eight patients had serious adverse events, none of which were treatment related. There were no treatment-related cardiac events or clinically significant changes in echocardiographic parameters or creatinine clearance by Cockcroft-Gault. INTERPRETATION: In this phase 2b study, ledipasvir combined with sofosbuvir for 12 weeks was safe and effective in patients with genotype 1 HCV infection and stage 4-5 chronic kidney disease who were not on dialysis. FUNDING: Gilead Sciences.

The lancet. Gastroenterology & hepatology published new progress about 58-97-9. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Computed Properties of 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Carmen Lafita-Navarro, M.; Perez-Castro, Lizbeth; Zacharias, Lauren G.; Barnes, Spencer; DeBerardinis, Ralph J.; Conacci-Sorrell, Maralice published the artcile< The transcription factors aryl hydrocarbon receptor and MYC cooperate in the regulation of cellular metabolism>, Quality Control of 58-97-9, the main research area is fibroblast cellular metabolism transcription factors aryl hydrocarbon receptor MYC; MYC (c-Myc); aryl hydrocarbon receptor (AHR); cancer; gene regulation; glioblastoma; glycolysis; metabolism; metabolomics; oncogene; pyrimidine.

The transcription factor AHR (aryl hydrocarbon receptor) drives the expression of genes involved in detoxification pathways in cells exposed to pollutants and other small mols. Moreover, AHR supports transcriptional programs that promote ribosome biogenesis and protein synthesis in cells stimulated to proliferate by the oncoprotein MYC. Thus, AHR is necessary for the proliferation of MYC-overexpressing cells. To define metabolic pathways in which AHR cooperates with MYC in supporting cell growth, here we used LC-MS-based metabolomics to examine the metabolome of MYC-expressing cells upon AHR knockdown. We found that AHR knockdown reduced lactate, S-lactoylglutathione, N-acetyl-L-alanine, 2-hydroxyglutarate, and UMP levels. Using our previously obtained RNA sequencing data, we found that AHR mediates the expression of the UMP-generating enzymes dihydroorotate dehydrogenase (quinone) (DHODH) and uridine monophosphate synthetase (UMPS), as well as lactate dehydrogenase A (LDHA), establishing a mechanism by which AHR regulates lactate and UMP production in MYC-overexpressing cells. AHR knockdown in glioblastoma cells also reduced the expression of LDHA (and lactate), DHODH, and UMPS but did not affect UMP levels, likely because of compensatory mechanisms in these cells. Our results indicate that AHR contributes to the regulation of metabolic pathways necessary for the proliferation of transformed cells.

Journal of Biological Chemistry published new progress about Animal gene Role: BSU (Biological Study, Unclassified), BIOL (Biological Study) (ALDOA). 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Quality Control of 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Fouad, Hanan M.; Sabry, Magda A.; Ahmed, Amal; Hassany, Mohamed; Al Soda, Mohamed F.; Abdel Aziz, Hossam published the artcile< Generic ledipasvir-sofosbuvir treatment for adolescents with chronic hepatitis C virus infection>, Recommanded Product: ((2R,3S,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate, the main research area is Egypt; HCV; adolescents; brand; generic ledipasvir-sofosbuvir.

We assessed the safety and efficacy of a generic form of ledipasvir-sofosbuvir for the treatment of hepatitis C virus infection in Egyptian adolescents and compared the results with those of treatment with the brand-named form. The generic form resulted in a high response rate, significant improvement in liver function, and mild adverse effects. These results are comparable with those of the brand form at a reduced price.

Journal of the Pediatric Infectious Diseases Society published new progress about 58-97-9. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Recommanded Product: ((2R,3S,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Boerekamps, Anne; Vanwolleghem, Thomas; van der Valk, Marc; van den Berk, Guido E.; van Kasteren, Marjo; Posthouwer, Dirk; Dofferhoff, Anthonius S. M.; van Hoek, Bart; Ramsoekh, Dewkoemar; Koopsen, Jelle; Schinkel, Janke; Florence, Eric; Arends, Joop E.; Rijnders, Bart J. published the artcile< 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)>, HPLC of Formula: 58-97-9, the main research area is review HIV HCV genotype sofosbuvir ledipasvir.

A review. This study evaluated the effectiveness of 8 wk sofosbuvir/ledipasvir (SOF/LDV) for genotype 4 HCV-infected DAA-naive HIV-pos. and neg. patients without cirrhosis. The primary outcome was SVR in the on-treatment study population, defined as an HCV RNA below the limit of detection 12 wk after the end of therapy in all patients that had completed the 8-wk treatment course of therapy and had an HCV RNA measurement ≥12 wk after the end of therapy. The study showed that 8 wk of SOF/LDV could be an effective therapy for non-cirrhotic HCV genotype 4 infected patients with an HCV RNA load ≤10 million IU/mL and is the first to evaluate the efficacy of 8 wk of SOF/LDV in a substantial number of HIV-coinfected patients.

Journal of Hepatology published new progress about Antiviral agents (Direct-acting). 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, HPLC of Formula: 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Zhang, Qian; Zhou, Dong-Dong; Li, Fan; Wang, Yin-Zhen; Yang, Feng-Qing published the artcile< Extraction of nucleobases, nucleosides and nucleotides by employing a magnetized graphene oxide functionalized with hydrophilic phytic acid and titanium(IV) ions>, Recommanded Product: ((2R,3S,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate, the main research area is nucleobase nucleoside nucleotide graphene oxide phytic acid titanium ion; Hydrophilic interaction liquid chromatography; Immobilized metal ion chromatography; Magnetic solid phase extraction; Nucleobase-based compounds.

A magnetite@graphene oxide nanocomposite was first coated with polyethylenimine and then modified with phytic acid and titanium(IV) ions. The high loading with Ti(IV) and the good hydrophilicity of PEI and PA result in a material that can be applied to the efficient extraction of highly polar nucleobases, nucleosides and nucleotides. The physicochem. properties of the composite were investigated by SEM, transmission electron microscopy, energy dispersive X-ray spectroscopy, Fourier transform IR spectroscopy, water contact angle measurements, thermogravimetric anal., and vibrating sample magnetometry. A series of parameters that affect extraction and elution under the conditions of immobilized metal affinity chromatog. and hydrophilic interaction liquid chromatog. were examined The analytes were eluted from the nanocomposites using 10 mM trisodium phosphate as the elution solution in the IMAC mode, and 50% methanol-water as elution solution in the HILIC mode. Figures of merit include (a) an intra-day precision of 0.1-1.0% in the IMAC mode; (b) an intra-day precision of 0.4%-0.8% in the HILIC mode; (c) detection limits between 1.8-2.8 ng mL-1 in the IMAC mode; and (d) detection limits of 4.0-10.5 ng mL-1 in the HILIC mode. The method was applied to the extraction of the nucleotides cytidine-5′-monophosphate, uridine-5′-monophosphate, guanosine-5′-monophosphate, and adenosine-5′-monophosphate, and the nucleobases and nucleosides hypoxanthine, adenosine, cytosine, inosine and cytidine from Cordyceps sinensis, Lentinus edodes and plasma samples.

Microchimica Acta published new progress about Blood plasma. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Recommanded Product: ((2R,3S,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem